company background image

Amyris NasdaqGS:AMRS Stock Report

Last Price


Market Cap







23 Mar, 2023


Company Financials +

AMRS Stock Overview

About the company

Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Snowflake Analysis

AMRS fundamental analysis
Snowflake Score
Future Growth1/6
Past Performance0/6
Financial Health0/6

My Notes

Capture your thoughts, links and company narrative

Amyris, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Amyris
Historical stock prices
Current Share PriceUS$1.45
52 Week HighUS$5.15
52 Week LowUS$0.99
1 Month Change5.07%
3 Month Change-25.26%
1 Year Change-66.67%
3 Year Change-33.79%
5 Year Change-78.33%
Change since IPO-99.41%

Recent News & Updates

Does This Valuation Of Amyris, Inc. (NASDAQ:AMRS) Imply Investors Are Overpaying?

Mar 22
Does This Valuation Of Amyris, Inc. (NASDAQ:AMRS) Imply Investors Are Overpaying?

Recent updates

Does This Valuation Of Amyris, Inc. (NASDAQ:AMRS) Imply Investors Are Overpaying?

Mar 22
Does This Valuation Of Amyris, Inc. (NASDAQ:AMRS) Imply Investors Are Overpaying?

At US$2.95, Is Amyris, Inc. (NASDAQ:AMRS) Worth Looking At Closely?

Oct 31
At US$2.95, Is Amyris, Inc. (NASDAQ:AMRS) Worth Looking At Closely?

Amyris Cost Breakdown

Oct 07

Recurring Marketing Exclusivity Deals Accelerate Amyris On Path To Profitability

Oct 01

Are Investors Undervaluing Amyris, Inc. (NASDAQ:AMRS) By 43%?

Sep 02
Are Investors Undervaluing Amyris, Inc. (NASDAQ:AMRS) By 43%?

Amyris: In Dire Need For Additional Capital

Aug 22

Amyris, Inc. (NASDAQ:AMRS) Just Reported, And Analysts Assigned A US$10.91 Price Target

Aug 12
Amyris, Inc. (NASDAQ:AMRS) Just Reported, And Analysts Assigned A US$10.91 Price Target

Amyris' Vertically-Integrated Business Model Transitioning From Investment Mode To Payoff Mode

Aug 08

Amyris: Revenues Need To Catch Expenses

Jul 08

Amyris: Elevated Cash Usage Causes Investors To Head For The Exits

May 11

Amryis Update: Building Value One Brick At A Time

Apr 28

Amyris: JVN Could Be Their Most Valuable Brand Yet

Mar 19

Amyris: Surviving The Perfect Storm

Feb 03

Amyris: MenoLabs Acquisition Extends The Platform Into New Markets

Jan 28

Amyris: Success With RebM Will Indicate A Manufacturing Advantage

Jan 19

Amyris: Enabling Environmentally Sustainable Beauty Products

Jan 03

Amyris: Well Positioned In The Cannabinoids Market

Dec 17

Amyris: Vaccine Upside

Nov 30

Amyris Buying Opportunity Created By Q3 Miss, Mega Convert And Potential Revolutionary COVID Vaccine

Nov 19

Amyris: Assessing Financial Capacity To Sustain Organic Growth, Carry COVID Research And Pay For Acquisition

Nov 04

Amyris: Cash Burn Accelerates As The Facade Is Cracking

Aug 16

Amyris Stock Forecast For 2021: Where Is It Headed?

Jul 28

Amyris: How Lead In Synthetic Biology Could Brew Up Big Profits

Jun 28

Finding Value In Beauty And Wellness Through Amyris

Jun 06

Amyris EPS beats by $0.52, beats on revenue

May 06

Amyris And Ingredion enter $100M partnership

May 03

Amyris’ acne formulation shows superior efficacy in early clinical study

Feb 02

Amyris Is Setting Up For A Monster Run

Dec 17

Amyris: Management Now Eyeing Asset Sales To Raise Much-Needed Additional Capital

Nov 09

Amyris, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Shareholder Returns

AMRSUS ChemicalsUS Market

Return vs Industry: AMRS underperformed the US Chemicals industry which returned -8.3% over the past year.

Return vs Market: AMRS underperformed the US Market which returned -14.2% over the past year.

Price Volatility

Is AMRS's price volatile compared to industry and market?
AMRS volatility
AMRS Average Weekly Movement11.8%
Chemicals Industry Average Movement5.2%
Market Average Movement6.5%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: AMRS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: AMRS's weekly volatility has decreased from 19% to 12% over the past year, but is still higher than 75% of US stocks.

Amyris, Inc. Fundamentals Summary

How do Amyris's earnings and revenue compare to its market cap?
AMRS fundamental statistics
Market CapUS$531.06m
Earnings (TTM)-US$528.51m
Revenue (TTM)US$269.85m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AMRS income statement (TTM)
Cost of RevenueUS$367.58m
Gross Profit-US$97.74m
Other ExpensesUS$430.77m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date


Earnings per share (EPS)-1.44
Gross Margin-36.22%
Net Profit Margin-195.86%
Debt/Equity Ratio-188.9%

How did AMRS perform over the long term?

See historical performance and comparison